231 related articles for article (PubMed ID: 23245760)
1. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.
Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC
Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760
[TBL] [Abstract][Full Text] [Related]
2. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.
Chamberlain SR; Mogg K; Bradley BP; Koch A; Dodds CM; Tao WX; Maltby K; Sarai B; Napolitano A; Richards DB; Bullmore ET; Nathan PJ
Psychopharmacology (Berl); 2012 Dec; 224(4):501-9. PubMed ID: 22752384
[TBL] [Abstract][Full Text] [Related]
3. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET
Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601
[TBL] [Abstract][Full Text] [Related]
5. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.
Nathan PJ; Bakker G
Psychopharmacology (Berl); 2021 May; 238(5):1255-1263. PubMed ID: 31900526
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.
Ignar DM; Goetz AS; Noble KN; Carballo LH; Stroup AE; Fisher JC; Boucheron JA; Brainard TA; Larkin AL; Epperly AH; Shearer TW; Sorensen SD; Speake JD; Hommel JD
J Pharmacol Exp Ther; 2011 Oct; 339(1):24-34. PubMed ID: 21712426
[TBL] [Abstract][Full Text] [Related]
8. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
[TBL] [Abstract][Full Text] [Related]
9. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET
Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953
[TBL] [Abstract][Full Text] [Related]
11. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.
Ziauddeen H; Nathan PJ; Dodds C; Maltby K; Miller SR; Waterworth D; Song K; Warren L; Hosking L; Zucchetto M; Bush M; Johnson LV; Sarai B; Mogg K; Bradley BP; Richards DB; Fletcher PC; Bullmore ET
J Clin Pharmacol; 2013 Oct; 53(10):1078-90. PubMed ID: 23934621
[TBL] [Abstract][Full Text] [Related]
12. The effects of repetitive transcranial magnetic stimulation in obese females with binge eating disorder: a protocol for a double-blinded, randomized, sham-controlled trial.
Maranhão MF; Estella NM; Cury ME; Amigo VL; Picasso CM; Berberian A; Campbell I; Schmidt U; Claudino AM
BMC Psychiatry; 2015 Aug; 15():194. PubMed ID: 26265452
[TBL] [Abstract][Full Text] [Related]
13. Opioid system in the medial prefrontal cortex mediates binge-like eating.
Blasio A; Steardo L; Sabino V; Cottone P
Addict Biol; 2014 Jul; 19(4):652-62. PubMed ID: 23346966
[TBL] [Abstract][Full Text] [Related]
14. Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorder.
Heal DJ; Hallam M; Prow M; Gosden J; Cheetham S; Choi YK; Tarazi F; Hutson P
J Psychopharmacol; 2017 Jun; 31(6):770-783. PubMed ID: 28376679
[TBL] [Abstract][Full Text] [Related]
15. From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour.
Nathan PJ; Bullmore ET
Int J Neuropsychopharmacol; 2009 Aug; 12(7):995-1008. PubMed ID: 19433009
[TBL] [Abstract][Full Text] [Related]
16. A pilot study linking reduced fronto-Striatal recruitment during reward processing to persistent bingeing following treatment for binge-eating disorder.
Balodis IM; Grilo CM; Kober H; Worhunsky PD; White MA; Stevens MC; Pearlson GD; Potenza MN
Int J Eat Disord; 2014 May; 47(4):376-84. PubMed ID: 24729034
[TBL] [Abstract][Full Text] [Related]
17. Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters.
Dodds CM; O'Neill B; Beaver J; Makwana A; Bani M; Merlo-Pich E; Fletcher PC; Koch A; Bullmore ET; Nathan PJ
Appetite; 2012 Aug; 59(1):27-33. PubMed ID: 22445776
[TBL] [Abstract][Full Text] [Related]
18. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.
Nathan PJ; O'Neill BV; Bush MA; Koch A; Tao WX; Maltby K; Napolitano A; Brooke AC; Skeggs AL; Herman CS; Larkin AL; Ignar DM; Richards DB; Williams PM; Bullmore ET
J Clin Pharmacol; 2012 Apr; 52(4):464-74. PubMed ID: 21610207
[TBL] [Abstract][Full Text] [Related]
19. Monetary reward processing in obese individuals with and without binge eating disorder.
Balodis IM; Kober H; Worhunsky PD; White MA; Stevens MC; Pearlson GD; Sinha R; Grilo CM; Potenza MN
Biol Psychiatry; 2013 May; 73(9):877-86. PubMed ID: 23462319
[TBL] [Abstract][Full Text] [Related]
20. Sweet taste pleasantness is modulated by morphine and naltrexone.
Eikemo M; Løseth GE; Johnstone T; Gjerstad J; Willoch F; Leknes S
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3711-3723. PubMed ID: 27538675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
